atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
- atai''s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess th…
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
- atai''s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess th…